Abiopharma

🔍 Pearson Mark (Director)

Company: Equitable Holdings, Inc. (EQH)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 1,387 shares of Common Stock at $23.18 per share (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 803,070.30 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,387 shares of Common Stock at $40.0271 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 801,683.30 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 1,387 shares of Employee Stock Option (right to buy) at $23.18 per share (Derivative)
  Date: 2026-04-15 | Code: M | Expires: 2030-02-26 | equity_swap_involved: 0 | shares_owned_after: 108,800.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: The sales reported and options exercised on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025.
• F2: Includes Restricted Stock Units and 11,011 shares acquired under the Employee Stock Purchase Plan.
• F3: This transaction was executed in multiple trades at prices ranging from $40.0000 to $40.0600. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
• F4: Grant of employee stock option under the Issuer's 2019 Omnibus Incentive Plan exempt under Rule 16b-3. The options vested in three installments beginning on February 26, 2021.